Search

Your search keyword '"Kitadani J"' showing total 2 results
Start Over Author "Kitadani J" Publisher international institute of anticancer research
2 results on '"Kitadani J"'

1. Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer.

Author

Hayata K, Ojima T, Nakamori M, Nakamura M, Katsuda M, Kitadani J, Takeuchi A, Tabata H, Maruoka S, and Yamaue H

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin adverse effects, Docetaxel, Drug Administration Schedule, Drug Combinations, Esophageal Neoplasms pathology, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy adverse effects, Neoplasm Grading, Oxonic Acid adverse effects, Survival Analysis, Taxoids adverse effects, Tegafur adverse effects, Treatment Outcome, Cisplatin administration & dosage, Esophageal Neoplasms drug therapy, Oxonic Acid administration & dosage, Taxoids administration & dosage, Tegafur administration & dosage
Abstract

Background/aim: Although the efficacy is limited, standard therapy for Stage II/III esophageal cancer in Japan includes neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil. A phase II trial was conducted on patients with resectable advanced esophageal cancer obtaining neoadjuvant chemotherapy with docetaxel, cisplatin plus S-1 (DCS)., Patients and Methods: A total of 40 patients were enrolled, each treated by the following DCS regimen: docetaxel 40 mg/m 2 , cisplatin 60 mg/m 2 on day 1, and S-1 80 mg/m 2 on days 1-14, repeated every four weeks, for a maximum of three cycles., Results: Clinical response rate was 76% and the pathological response rate (Grade 2/3) was 33%. Hematological toxicities of Grade 3/4 were leukopenia 50%, neutropenia 68%, and febrile neutropenia 18%., Conclusion: Neoadjuvant chemotherapy with DCS is a feasible therapeutic strategy for patients with advanced thoracic esophageal squamous cell carcinoma., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

2. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.

Author

Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Iwahashi M, and Yamaue H

Subjects
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Chemotherapy, Adjuvant, Cisplatin adverse effects, Disease-Free Survival, Docetaxel, Drug Administration Schedule, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma, Feasibility Studies, Female, Fluorouracil adverse effects, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neutropenia chemically induced, Risk Factors, Taxoids adverse effects, Time Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Cisplatin administration & dosage, Esophageal Neoplasms drug therapy, Fluorouracil administration & dosage, Neoadjuvant Therapy, Taxoids administration & dosage
Abstract

Background: The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE)., Patients and Methods: The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m(2) on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m(2) on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m(2) on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF., Results: The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56%) than in the CF group (0%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40%) than in the CF group (11%) (p=0.0153)., Conclusion: This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results